Loading
KB
Kaleido Biosciences, Inc. Stock: price and insider trades · United States
Kaleido Biosciences, Inc.: what insiders have been doing
Only a handful of insider records exist for Kaleido Biosciences, Inc., the last one from 2 March 2022, too few to describe a trend. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
2
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended December 2021 · cache
US$0.00
Analyst consensus
Income statement
RevenueUS$1.1M
EBITDA-US$85.1M-7708% margin
Net income-US$90.3M-8178.3% margin
Valuation
P/Book0.0x
Beta40.04
Balance sheet & cash
Market capUS$4.3k
Total debtUS$21.7M
Free Cash Flow-US$78.2M
Debt / Equity205%
Profitability & ownership
ROE-580.6%
ROA-99.9%
% insiders0.0%
% institutions0.1%
Last declaration on 2 March 2022
Declarations2 total
2,087 shares@ US$1.49100.0% of flowRestricted Stock UnitsSEC:0001209191-22-014692:0
2,046 shares@ US$1.49100.0% of flowRestricted Stock UnitsSEC:0001209191-22-014673:0
2 of 2 declarations
About Kaleido Biosciences, Inc.
Kaleido Biosciences, Inc. is a company focused on developing microbiome-based therapies to treat various diseases. It emphasizes innovation in the healthcare and pharmaceutical sectors.
